Stéphane Oudard

Research interests

Publications

• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00487-9

• Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer

  Immunity · 2022 · https://doi.org/10.1016/j.immuni.2022.02.001

• Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

  New England Journal of Medicine · 2021 · 10.1056/nejmoa2106391

• Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00152-2

• Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00152-2

• Bone health in cancer: ESMO Clinical Practice Guidelines

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.07.019

• Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30413-9

• Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal

  Cell · 2018 · https://doi.org/10.1016/j.cell.2018.02.020

• Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1715546

• Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)33297-x

• IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30408-9

• Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.65.5597

• Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer

  European Urology · 2014 · https://doi.org/10.1016/j.eururo.2014.10.001

• Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy

  JNCI Journal of the National Cancer Institute · 2013 · https://doi.org/10.1093/jnci/djt280

• Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.48.5268

• Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

  The Lancet Oncology · 2013 · https://doi.org/10.1016/s1470-2045(13)70479-0

• PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

  Cancer Research · 2012 · https://doi.org/10.1158/0008-5472.can-12-2606

• Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

  Cancer and Metastasis Reviews · 2011 · https://doi.org/10.1007/s10555-011-9281-4

• Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer

  European Urology · 2011 · https://doi.org/10.1016/j.eururo.2011.11.009

• Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review

  European Urology · 2011 · https://doi.org/10.1016/j.eururo.2011.06.041

• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

  The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(10)61389-x

• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

  The Lancet · 2008 · https://doi.org/10.1016/s0140-6736(08)61039-9

• Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

  New England Journal of Medicine · 2007 · https://doi.org/10.1056/nejmoa065044

• Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

  New England Journal of Medicine · 2007 · https://doi.org/10.1056/nejmoa060655

• Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

  New England Journal of Medicine · 2004 · https://doi.org/10.1056/nejmoa040720

Current projects

No projects listed.